Notably, a study in lung cancer found that silencing HSPH1 significantly increased the anti-tumour effect of gefitinib in non-small cell lung cancer (6), suggesting that HSPH1 may be a potential biomarker for the diagnosis, targeted therapy and prognostic evaluation of a variety of human tumours. This evidence concerns the gene HSPH1 and neoplasm.